Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2025

BUY
$1.44 - $3.29 $19,789 - $45,214
13,743 New
13,743 $23,000
Q2 2024

Oct 08, 2025

BUY
$2.46 - $4.05 $33,807 - $55,659
13,743 New
13,743 $35,000
Q1 2024

Oct 08, 2025

BUY
$3.19 - $5.32 $43,840 - $73,112
13,743 New
13,743 $57,000
Q1 2024

May 07, 2024

SELL
$3.19 - $5.32 $92 - $154
-29 Reduced 0.21%
13,743 $57,000
Q4 2023

Oct 08, 2025

BUY
$1.28 - $3.32 $17,628 - $45,723
13,772 New
13,772 $45,000
Q4 2023

Feb 01, 2024

SELL
$1.28 - $3.32 $21 - $56
-17 Reduced 0.12%
13,772 $46,000
Q3 2023

Oct 08, 2025

BUY
$2.0 - $3.23 $27,578 - $44,538
13,789 New
13,789 $27,000
Q3 2023

Nov 07, 2023

BUY
$2.0 - $3.23 $160 - $258
80 Added 0.58%
13,789 $28,000
Q2 2023

Oct 08, 2025

BUY
$2.91 - $3.53 $39,893 - $48,392
13,709 New
13,709 $43,000
Q2 2023

Aug 07, 2023

SELL
$2.91 - $3.53 $17,361 - $21,059
-5,966 Reduced 30.32%
13,709 $43,000
Q1 2023

Oct 08, 2025

BUY
$3.4 - $5.11 $20,284 - $30,486
5,966 Added 43.52%
19,675 $68,000
Q1 2023

May 02, 2023

BUY
$3.4 - $5.11 $20,284 - $30,486
5,966 Added 43.52%
19,675 $68,000
Q4 2022

Oct 08, 2025

BUY
$4.84 - $11.58 $66,351 - $158,750
13,709 New
13,709 $70,000
Q4 2022

Jan 30, 2023

SELL
$4.84 - $11.58 $38 - $92
-8 Reduced 0.06%
13,709 $70,000
Q3 2022

Nov 08, 2022

BUY
$8.57 - $13.1 $368 - $563
43 Added 0.31%
13,717 $136,000
Q2 2022

Aug 04, 2022

BUY
$7.96 - $12.43 $183 - $285
23 Added 0.17%
13,674 $115,000
Q1 2022

May 05, 2022

BUY
$11.62 - $15.92 $68,941 - $94,453
5,933 Added 76.87%
13,651 $172,000
Q4 2021

Feb 02, 2022

BUY
$13.93 - $23.62 $78,258 - $132,697
5,618 Added 267.52%
7,718 $122,000
Q3 2021

Nov 02, 2021

BUY
$20.8 - $31.93 $43,680 - $67,053
2,100 New
2,100 $53,000

Others Institutions Holding IPSC

About Century Therapeutics, Inc.


  • Ticker IPSC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,881,800
  • Market Cap $27.7M
  • Description
  • Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...
More about IPSC
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.